Saluda Medical secures $40m in series D financing

This article was originally published here

Saluda Medical, a medical device company developing a platform of closed-loop neuromodulation technologies based on neural response to stimulation, has announced that it has secured AU$53m (USD$40m) in an all-equity financing round led by new investor, Action Potential Venture Capital (APVC), a GSK fund that invests in companies developing bioelectronic medicines.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply